The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of FOLFOX biweekly cetuximab as first-line therapy for patients with nonresectable metastatic colorectal cancer (CELINE trial): Multicenter phase II trial.
Ken Kondo
No relevant relationships to disclose
Masanori Kotake
No relevant relationships to disclose
Kenji Doden
No relevant relationships to disclose
Yoshinori Munemoto
No relevant relationships to disclose
Kenji Kobayashi
No relevant relationships to disclose
Genichi Nishimura
No relevant relationships to disclose
Kazuhiko Omote
No relevant relationships to disclose
Junichi Sakamoto
No relevant relationships to disclose